Report

Global Synthetic Stem Cells Market Size study, by Application, by End-Use and Regional Forecasts 2021-2027

  • Publish Date: Mar,2022
  • Report ID: QI037
  • Page : 250
  • Report Type : PDF (Email)
Global Synthetic Stem Cells Market is valued at approximately USD 12 million in 2021 and is anticipated to grow with a healthy growth rate of more than 23.8 % over the forecast period 2021-2027. Stem cell therapies work by promoting endogenous repair that is, they help damaged tissue in repairing itself by secreting paracrine factors, including proteins and genetic materials. While stem cell therapies can be effective, they are also associated with some risks of both tumor growth and immune rejection. The increasing incidences of various cardiovascular diseases and government investment in research & development activities have led to the adoption of Synthetic Stem Cells across the forecast period. For Instance: as per the WHO, An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Also, with the development of stem cells for stem line banking, the adoption & demand for Synthetic Stem Cells is likely to increase the market growth during the forecast period. However, unclear and unstructured regulations impede the growth of the market over the forecast period of 2021-2027.

The key regions considered for the global Synthetic Stem Cells market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the growing investment in research and development activities. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as rising population, rising incidences of injuries and improving healthcare infrastructure would create lucrative growth prospects for the Synthetic Stem Cells market across Asia-Pacific region.

Major market players included in this report are:
Caladrius Biosciences
Sangamo Therapeutics
Athersys
Pluristem Therapeutics
Cellular Biomedicine Group
Vericel
ThermoGenesis Corp.
Gamida Cell
TheraCell Inc.
VeraTech Biologics, LLc,
BrainstormCell Therapeutics

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Application:
Cardiovascular Disease
Neurological Disorders
Cancer
Diabetes
Gastrointestinal
Musculoskeletal Disorder
By End Use:
Hospitals and Surgical Centers
Academic Institutes
Research Laboratories
Pharmaceutical and Biotechnology Companies
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Synthetic Stem Cells Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Caladrius Biosciences
Sangamo Therapeutics
Athersys
Pluristem Therapeutics
Cellular Biomedicine Group
Vericel
ThermoGenesis Corp.
Gamida Cell
TheraCell Inc.
VeraTech Biologics, LLc,
BrainstormCell Therapeutics